Glycopeptide-resistant staphylococcus aureus

International Journal of Clinical Practice, Supplement

Volumn , Issue 115, 2000, Pages 66-71

  Edmond, M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; DALFOPRISTIN; EVERNIMICIN; LINEZOLID; LYSOSTAPHIN; METICILLIN; ORITAVANCIN; QUINUPRISTIN; VANCOMYCIN;

AIRBORNE INFECTION; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ARTHRITIS; CONFERENCE PAPER; DOSE RESPONSE; DRUG SENSITIVITY; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIDRUG RESISTANCE; OSTEOMYELITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TOXIC SHOCK SYNDROME; TREATMENT FAILURE; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; GLYCOPEPTIDES; HUMANS; METHICILLIN RESISTANCE; PENICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 0034482822     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. The economic impact of Staphylococcus aureus infection in New York City hospitals
2. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs?
3. Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus
4. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
5. Reduced susceptibility of Staphylococcus aureus to vancomycin -Japan, 1996
6. Four pediatric deaths from Community Acquired Methicillin-Resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999
7. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee
8. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals
9. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk
10. Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community
11. Methicillin-resistant Staphylococcus aureus in two child care centers
12. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
13. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
14. Antimicrobial resistance in key bloodstream bacterial isolates: Electronic surveillance with the Surveillance Network Database - USA
15. Susceptibility of 302 methicillin-resistant Staphylo-coccus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. SENTRY Participants Group
16. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
17. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
18. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
19. Vancomycin-resistant Staphylococcus aureus
20. Vancomycin resistant staphylococcus reported in Hong Kong
21. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
22. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
23. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia
24. Evaluation of bactericidal activities of LY333328, vancomycin, telcoplanin, ampicillin-sulbactam, trovafloxacin and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods
25. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin
26. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide Intermediate Staphylococcus aureus Working Group
27. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus
28. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
29. Vancomycin-resistant Staphylococcus aureus: Perspectives on measures needed for control
30. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee